Wedbush Estimates Xencor’s Q3 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Equities research analysts at Wedbush increased their Q3 2025 earnings estimates for Xencor in a research report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.51) per share for the quarter, up from their prior forecast of ($0.79). Wedbush currently has a “Outperform” rating and a $26.00 target price on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor’s Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($2.43) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.45) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($3.75) EPS.

Several other research firms have also weighed in on XNCR. William Blair began coverage on shares of Xencor in a research note on Monday, April 21st. They issued an “outperform” rating on the stock. Wells Fargo & Company decreased their target price on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, Barclays decreased their target price on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, Xencor has an average rating of “Moderate Buy” and a consensus target price of $26.43.

Xencor Stock Performance

Xencor stock opened at $7.23 on Monday. The firm has a market cap of $515.64 million, a PE ratio of -3.01 and a beta of 0.89. The firm’s 50 day moving average price is $8.67 and its two-hundred day moving average price is $10.87. Xencor has a twelve month low of $7.07 and a twelve month high of $27.24.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.37. The firm had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The company’s revenue for the quarter was up 82.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.07) EPS.

Institutional Trading of Xencor

Several large investors have recently modified their holdings of the company. Creative Planning boosted its holdings in shares of Xencor by 25.3% during the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 3,661 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Xencor by 9.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,525 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its holdings in Xencor by 16.1% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 16,470 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 2,281 shares during the period. Geode Capital Management LLC boosted its holdings in Xencor by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,703,664 shares of the biopharmaceutical company’s stock valued at $13,393,000 after purchasing an additional 29,316 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Xencor by 82.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,982 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 2,709 shares during the period.

Insider Buying and Selling

In related news, Director Kurt A. Gustafson sold 2,993 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 20,183 shares of the company’s stock, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director directly owned 19,183 shares of the company’s stock, valued at approximately $176,867.26. This represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,194 shares of company stock valued at $103,209. Company insiders own 5.23% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.